{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:25:38Z","timestamp":1772580338950,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Science & Engineering Research Board \u2013 Department of Science & Technology (SERB-DST), Govt. of India","award":["SERB\/ECR\/2017\/000317"],"award-info":[{"award-number":["SERB\/ECR\/2017\/000317"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.pharep.2019.05.008","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T12:15:21Z","timestamp":1557922521000},"page":"958-967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy"],"prefix":"10.1007","volume":"71","author":[{"given":"Vajir","family":"Malek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2019.05.008_bib0005","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopha.2017.04.024","article-title":"Neprilysin inhibitors: a new hope to halt the diabetic cardiovascular and renal complications?","volume":"90","author":"Malek","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharep.2019.05.008_bib0010","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","author":"Velazquez","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2019.05.008_bib0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ejhf.474","article-title":"LCZ696, an angiotensin receptor\u2013neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin\u2010induced diabetic mice","volume":"18","author":"Suematsu","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharep.2019.05.008_bib0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cardfail.2017.12.010","article-title":"LCZ696 (sacubitril\/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis and vasculopathy in a rat model of chronic kidney disease","volume":"24","author":"Suematsu","year":"2018","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharep.2019.05.008_bib0025","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yjmcc.2017.06.003","article-title":"LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy","volume":"108","author":"Xia","year":"2017","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharep.2019.05.008_bib0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2018.05.124","article-title":"Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction","volume":"281","author":"Docherty","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharep.2019.05.008_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bcpt.12912","article-title":"The combination of Valsartan and Sacubitril in the treatment of hypertension and heart failure\u2013an update","volume":"122","author":"Nielsen","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharep.2019.05.008_bib0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/cvr\/cvy226","article-title":"Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy","volume":"115","author":"Malek","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharep.2019.05.008_bib0045","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1111\/bph.13946","article-title":"Diminazene aceturate prevents nephropathy by increasing glomerular Ace2 and At2 receptor expression in a rat model of type1 diabetes","volume":"174","author":"Goru","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2019.05.008_bib0050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/Angiotensin-(1\u20137)\/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1\u20137)","volume":"98","author":"Santos","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharep.2019.05.008_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/594361","article-title":"Protective role of the ACE2\/Ang-(1\u20139) axis in cardiovascular remodeling","volume":"2012","author":"Ocaranza","year":"2012","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.pharep.2019.05.008_bib0060","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.113.01337","article-title":"Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology","volume":"62","author":"Qi","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.pharep.2019.05.008_bib0065","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/europace\/euu070","article-title":"Activation of angiotensin-converting enzyme 2 improves cardiac electrical changes in ventricular repolarization in streptozotocin-induced hyperglycaemic rats","volume":"16","author":"Coutinho","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.pharep.2019.05.008_bib0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-med-052914-091923","article-title":"New pharmacological strategies to increase cGMP","volume":"67","author":"Buglioni","year":"2016","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.pharep.2019.05.008_bib0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.lfs.2019.02.027","article-title":"Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy","volume":"221","author":"Malek","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.pharep.2019.05.008_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1016\/j.pharep.2019.05.008_bib0085","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1042\/BCJ20160595","article-title":"Histone H2AK119 and H2BK120 mono-ubiquitination modulate SET7\/9 and SUV39H1 in type 1 diabetes-induced renal fibrosis","volume":"473","author":"Goru","year":"2016","journal-title":"Biochem J"},{"key":"10.1016\/j.pharep.2019.05.008_bib0090","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1007\/s00125-015-3600-1","article-title":"50 years forward: mechanisms of hyperglycaemia-driven diabetic complications","volume":"58","author":"Russell","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharep.2019.05.008_bib0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ki.2015.107","article-title":"Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats","volume":"88","author":"Roksnoer","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharep.2019.05.008_bib0100","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3390\/ijms19061712","article-title":"The impact of the nitric oxide (NO)\/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective","volume":"19","author":"Krishnan","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharep.2019.05.008_bib0105","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/CIRCRESAHA.117.303776","article-title":"Contemporary approaches to modulating the nitric oxide-cGMP pathway in cardiovascular disease","volume":"120","author":"Kraehling","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.pharep.2019.05.008_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-018-0690-1","article-title":"A concise discussion of the regulatory role of cGMP kinase I in cardiac physiology and pathology","volume":"113","author":"Hofmann","year":"2018","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharep.2019.05.008_bib0115","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/cvr\/cvy039","article-title":"Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase","volume":"114","author":"Frankenreiter","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharep.2019.05.008_bib0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/HYPERTENSIONAHA.118.11081","article-title":"Natriuretic peptides in cardiovascular and metabolic crosstalk: implications for hypertension management","volume":"72","author":"Jordan","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.pharep.2019.05.008_bib0125","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/hr.2009.74","article-title":"Devil and angel in the renin\u2013angiotensin system: ACE\u2013angiotensin II\u2013AT1 receptor axis vs. ACE2\u2013angiotensin-(1\u20137)\u2013mas receptor axis","volume":"32","author":"Iwai","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharep.2019.05.008_bib0130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharep.2019.05.008_bib0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41419-017-0135-z","article-title":"Cellular death, reactive oxygen species (ROS) and diabetic complications","volume":"9","author":"Volpe","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pharep.2019.05.008_bib0140","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/CIRCRESAHA.116.306819","article-title":"Epigenetic changes in diabetes and cardiovascular risk","volume":"118","author":"Keating","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.pharep.2019.05.008_bib0145","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2337\/db12-1648","article-title":"SIRT1, p66Shc, and Set7\/9 in vascular hyperglycemic memory bringing all the strands together","volume":"62","author":"Paneni","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.pharep.2019.05.008_bib0150","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1681\/ASN.2010060633","article-title":"Epigenetic histone methylation modulates fibrotic gene expression","volume":"21","author":"Sun","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharep.2019.05.008_bib0155","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCRESAHA.112.266171","article-title":"Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells","volume":"110","author":"Okabe","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.pharep.2019.05.008_bib0160","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCGENETICS.114.000671","article-title":"Adverse epigenetic signatures by histone methyltransferase set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus","volume":"8","author":"Paneni","year":"2015","journal-title":"Circ Cardiovas Genet."}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114019301185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114019301185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:38:03Z","timestamp":1752611883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2019.05.008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1734114019301185"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2019.05.008","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2019.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}